CN113828426A - Method and device for extracting platelet-rich plasma from blood - Google Patents

Abstract

Translated fromChinese

本发明涉及从血液中提取富血小板血浆的方法及装置。方法包括：使内含经抗凝处理的血液的第一注射器的锥头朝下，并将第一注射器以300g至3000g的相对离心力离心5分钟至45分钟，第一注射器内的内容物自上而下分层为贫血小板血浆层、富血小板血浆层和红细胞层；保持第一注射器的锥头朝下，并将第一注射器内的红细胞层经由联通件转移至收集容器内；保持第一注射器的锥头朝下，并将第一注射器内的富血小板血浆层经由联通件转移至第二注射器内，以使第二注射器内仅含富血小板血浆层；将第二注射器内的富血小板血浆和第三注射器内的凝血剂转移至喷涂装置，并使喷涂装置内的富血小板血浆和凝血剂混合产生富血小板凝胶并从喷涂装置内喷出。

The present invention relates to a method and apparatus for extracting platelet-rich plasma from blood. The method includes: making the cone head of a first syringe containing anticoagulated blood face down, centrifuging the first syringe with a relative centrifugal force of 300g to 3000g for 5 minutes to 45 minutes, and the content in the first syringe from the top The lower layer is the platelet-poor plasma layer, the platelet-rich plasma layer and the red blood cell layer; keep the cone head of the first syringe facing down, and transfer the red blood cell layer in the first syringe to the collection container through the connecting piece; keep the first syringe The cone head of the first syringe is facing down, and the platelet-rich plasma layer in the first syringe is transferred to the second syringe through the connecting piece, so that the second syringe only contains the platelet-rich plasma layer; the platelet-rich plasma in the second syringe and the The coagulant in the third syringe is transferred to the spraying device, and the platelet-rich plasma and the coagulant in the spraying device are mixed to produce a platelet-rich gel and sprayed from the spraying device.

Description

Method and device for extracting platelet-rich plasma from blood

Technical Field

The invention relates to the technical field of medical instruments, in particular to a method and a device for extracting platelet-rich plasma from blood.

Background

After centrifugation, the blood is divided into three layers, namely a Platelet-Poor Plasma (PPP) layer, a Platelet-Rich Plasma (PRP) layer and a red blood cell layer from top to bottom. Liquid PRP is generally injected to a treatment site to accelerate wound healing and repair cartilage damage, etc., and gel-like PRP is suitable for adhering, filling and covering wounds and preventing loss of growth factors, and thus is widely used in the medical field. The PRP is usually extracted by primary centrifugation or secondary centrifugation, but the primary centrifugation is usually performed by extracting the intermediate PRP layer, which causes the PRP in the intermediate layer to diffuse into the upper PPP layer or the lower erythrocyte layer, resulting in low PRP extraction concentration and recovery rate. The second centrifugation method requires two centrifugation processes, which obviously makes the required extraction process more complicated and time-consuming. In addition, the liquid PRP obtained by extraction is generally directly injected in the prior art, so the using effect is more general.

Therefore, there is a need in the art for an extraction method and apparatus that provides high extraction concentration and recovery, simple and time-consuming extraction process, and good utility.

Disclosure of Invention

The present invention aims to provide a method for extracting platelet-rich plasma from blood which can solve at least some of the above problems.

The present invention also aims to provide a device for extracting platelet-rich plasma from blood, applying the above improved method.

According to one aspect of the present invention, there is provided a method of extracting platelet rich plasma from blood, the method comprising: the method comprises the following steps of (1) enabling a conical head of a first syringe containing anticoagulated blood to face downwards, and centrifuging the first syringe for 5 to 45 minutes at a relative centrifugal force of 300 to 3000g, wherein the content in the first syringe is divided into a platelet poor plasma layer, a platelet rich plasma layer and a red blood cell layer from top to bottom; maintaining the first syringe with its conical tip facing downward and connecting the first syringe in fluid communication to a collection container via a communication member, such that the layer of red blood cells in the first syringe is transferred into the collection container via the communication member; maintaining the first syringe with its conical tip facing downward and connecting the first syringe in fluid communication to a second syringe via the communication member, and transferring the platelet rich plasma layer in the first syringe into the second syringe via the communication member such that the second syringe contains only the platelet rich plasma layer; connecting the second syringe containing platelet rich plasma and a third syringe containing a clotting agent in fluid communication to a spray device; and transferring the platelet-rich plasma in the second syringe and the coagulant in the third syringe to the spraying device, mixing the platelet-rich plasma and the coagulant in the spraying device to generate platelet-rich gel, and spraying the platelet-rich gel from the spraying device.

Compared with the prior art, the invention can ensure the clear layering of the blood in the first injector after centrifugal movement and avoid damaging blood cells by setting the relative centrifugal force and the centrifugal time range of the first injector for centrifugal movement. In addition, through assembling first syringe, UNICOM's piece, collection container and second syringe, only need carry out once centrifugal operation and can realize PRP's extraction, it is short and simple structure consuming time. The PRP can be transferred into the second injector by operating the first injector, which enables the bulk transfer of the PRP layer while reducing interlayer disturbances, thereby improving PRP recovery. In addition, by operating the advancing degree of the first plunger rod, a desired PRP concentration can be obtained as required, and the applicability is high. Finally, by connecting the second syringe and the third syringe through the spraying device, the PRP gel can be prepared, and the using effect of the prepared PRP is further improved.

Preferably, the anticoagulated blood is obtained by: drawing anticoagulant using the first syringe; collecting blood using the first syringe, the first syringe drawing a ratio of anticoagulant to collected blood of 1: 9; and mixing the anticoagulant and the blood in the first syringe to obtain anticoagulated blood.

Preferably, the first syringe collects blood in a volume ranging from 10 ml to 100 ml.

Preferably, the first syringe is centrifuged at a relative centrifugal force of 500g to 1500g for 15 minutes to 45 minutes.

Preferably, the first syringe is centrifuged at a relative centrifugal force of 1501g to 2500g for 10 minutes to 30 minutes.

Preferably, the first syringe is centrifuged at a relative centrifugal force of 2501g to 3500g for 5 minutes to 15 minutes.

Preferably, the first syringe transfers the layer of contained red blood cells into the collection container at a rate of no more than 0.5 ml per second.

Preferably, the first syringe transfers only a portion of the layer of red blood cells to the collection container, leaving a remaining portion of the layer of red blood cells within the first syringe.

Preferably, the volume of red blood cells left in the first syringe ranges from 3% to 10% of the volume of the collected blood.

Preferably, the time required for the first syringe to transfer the platelet rich plasma layer into the second syringe exceeds 10 seconds.

Preferably, the coagulant is obtained by: withdrawing saline using the third syringe; and (3) preparing thrombin by using the third syringe, and mixing the physiological saline in the third syringe with the thrombin to obtain the coagulant.

According to another aspect of the present invention, there is provided a device for extracting platelet rich plasma from blood for performing the aforementioned method, the device comprising: a first syringe containing anticoagulated blood and centrifuging the anticoagulated blood for 5 to 45 minutes at a relative centrifugal force of 300 to 3000g in a state that a conical head is downward, wherein the content in the first syringe is divided into a platelet poor plasma layer, a platelet rich plasma layer and a red blood cell layer from top to bottom; the first injector is detachably connected to the communicating piece in a conical head-down posture; a collection container detachably connected to the communication member so that the first syringe and the collection container are communicated via the communication member, and the erythrocyte layer in the first syringe is transferred into the collection container via the communication member; and the second syringe is detachably connected to the communicating piece, so that the platelet rich plasma layer in the first syringe is transferred into the second syringe through the communicating piece, and the platelet rich plasma layer is only contained in the second syringe to extract the platelet rich plasma. The second syringe containing platelet-rich plasma is detachably connected to the spraying device after being detached from the communicating piece; and a third syringe which contains a coagulant and is detachably connected with the spraying device so as to enable the second syringe, the third syringe and the spraying device to be communicated in a fluid mode, wherein the platelet-rich plasma in the second syringe and the coagulant in the third syringe can be transferred to the spraying device and mixed in the spraying device to generate platelet-rich gel and then the platelet-rich gel is sprayed out.

Preferably, the conical heads of the first syringe, the collection container, the second syringe and the third syringe are all detachably connected with sheaths.

Preferably, the communication member is a two-way valve or a three-way valve.

Preferably, the spray coating device comprises: a holding frame holding the second syringe and the third syringe juxtaposed to each other therein; a push plate mounted to the heads of the second syringe and the third syringe core rod; the spray tee joint comprises two liquid inlets and a liquid outlet, and the two liquid inlets of the spray tee joint are respectively connected to the conical heads of the second injector and the third injector; a nozzle connected to the liquid outlet of the spray tee to communicate the second and third syringes and the nozzle, wherein the platelet rich in the second syringe and the coagulant in the third syringe are transferred into the nozzle to mix to produce a gel in the nozzle; and the spray head is arranged in the nozzle to spray the atomized gel.

Additional features and advantages of the invention will be set forth in part in the description which follows, and in part will be apparent to those having ordinary skill in the art upon examination of the following, or may be learned from the practice of the invention.

Drawings

Embodiments of the invention are described in detail below with reference to the attached drawing figures, wherein:

FIG. 1 is a first schematic view of an apparatus for extracting platelet rich plasma from blood according to the present invention;

FIG. 2 is a second schematic view of an apparatus for extracting platelet rich plasma from blood according to the present invention;

fig. 3 is a schematic flow diagram of a method of extracting platelet rich plasma from blood according to the present invention.

Description of reference numerals:

10-a first syringe; 11-a communication member; 12-a collection vessel; 13-a second syringe; 14-a third syringe; 15-a spraying device; 151-a support frame; 152-push plate.

Detailed Description

Referring now to the drawings, illustrative embodiments of the disclosed method and apparatus for extracting platelet rich plasma from blood will be described in detail. Although the drawings are provided to present some embodiments of the invention, the drawings are not necessarily to scale of particular embodiments, and certain features may be exaggerated, removed, or partially sectioned to better illustrate and explain the present disclosure. The position of some components in the drawings can be adjusted according to actual requirements on the premise of not influencing the technical effect. The appearances of the phrase "in the drawings" or similar language in the specification are not necessarily referring to all drawings or examples.

Certain directional terms used hereinafter to describe the drawings, such as "inner", "outer", "above", "below", and other directional terms, will be understood to have their normal meaning and refer to those directions as they normally relate to when viewing the drawings. Unless otherwise indicated, the directional terms described herein are generally in accordance with conventional directions as understood by those skilled in the art.

The terms "first," "second," and the like, as used herein, do not denote any order, quantity, or importance, but rather are used to distinguish one element from another.

As used herein, the terms "joined," "connected," and the like, are intended to encompass both components which are indirectly joined together through intervening layers (e.g., adhesives, welds, etc.) or intermediate members (e.g., connectors, transitions, etc.), and components which are directly joined together without any intervening layers (e.g., adhesives, welds, etc.) or intermediate members (e.g., connectors, transitions, etc.).

Fig. 1 and 2 show a platelet-rich plasma extraction device of the present invention, which is simpler than the prior art extraction device, and can ensure the concentration of extracted PRP and improve the PRP usage effect while simplifying the extraction complexity and reducing the extraction time. The device may include, among other things, afirst syringe 10, acommunication 11, acollection container 12, asecond syringe 13, aspray device 15, and athird syringe 14.

Specifically, thefirst syringe 10 includes a barrel, a core rod located on the inner wall of the barrel and capable of sliding along the inner wall of the barrel in a sealing manner, and a conical head located at one end of the barrel. Alternatively, thefirst syringe 10, thesecond syringe 13 and thethird syringe 14 may also be medical devices having similar functions in the art. Thecommunication member 11 may be a two-way valve or a three-way valve.

In case thecommunication member 11 is designed as a two-way valve, the two-way valve may comprise a two-way pipe, a two-way valve spool located in the two-way pipe and a rotary piston which may control the rotation of the two-way valve spool. The rotating piston is rotated to enable the channel in the two-way valve core to align with the two ends of the two-way pipe or enable the two-way valve core to block the two-way pipe, so that containers connected to the two ends of the two-way pipe are communicated or disconnected. Wherein thefirst syringe 10 and thecollection container 12 may be detachably connected to both ends of a two-way valve, respectively, such that thefirst syringe 10 and thecollection container 12 are connected or disconnected via the two-way valve, so that the contents in thefirst syringe 10 may be transferred into thecollection container 12 or prevented from being transferred therebetween via the two-way valve by pushing thefirst syringe 10 core rod. In practice, thecollection container 12 may be a syringe or a waste container. In the case where thecollection container 12 is detached from the two-way valve, thesecond syringe 13 may be connected to the two-way valve instead of thecollection container 12 to be connected to thefirst syringe 10 via the two-way valve, so that the contents in thefirst syringe 10 may be transferred into thesecond syringe 13 via the two-way valve by pushing on thefirst syringe 10 plunger. Alternatively, in the case where both thefirst syringe 10 and thecollection container 12 are detached from the two-way valve, thefirst syringe 10 and thesecond syringe 13 may be respectively connected to both ends of a new unused two-way valve to communicate thefirst syringe 10 and thesecond syringe 13 via the new unused two-way valve, so that the transferred contents are not mixed with the remaining substance in the two-way valve during the transfer of the contents of thefirst syringe 10 into thesecond syringe 13.

In case thecommunication member 11 is designed as a three-way valve, the three-way valve may be configured to include a three-way pipe, a three-way spool located within the three-way pipe, and a rotary piston that may control the rotation of the three-way spool. The channel in the three-way valve core can be communicated with any two ports of the three-way pipe by rotating the rotary piston, so that any two containers connected to the three ports of the three-way pipe are communicated and disconnected with the other container. Wherein, thefirst syringe 10, thecollection container 12 and thesecond syringe 13 can be respectively connected to three ends of a three-way valve, so that the rotary piston of the three-way valve is adjusted as required to enable thefirst syringe 10 to be communicated with thecollection container 12 but not communicated with thesecond syringe 13, or thefirst syringe 10 is adjusted to be not communicated with thecollection container 12 but communicated with thesecond syringe 13, and then the content in thefirst syringe 10 can be transferred into thecollection container 12 or thesecond syringe 13 as required.

Alternatively, one end of the three-way valve may be designed as a vent end, and thefirst syringe 10 and thecollection container 12 may be connected to the other two ends of the three-way valve, and the contents of thefirst syringe 10 may be transferred into thecollection container 12 via the three-way valve by turning the rotary piston to close the vent end. Thecollection container 12 is then either three-way disconnected and thesecond syringe 13 is connected to the three-way valve instead of thecollection container 12, or both thefirst syringe 10 and thecollection container 12 are disconnected from the three-way valve and thefirst syringe 10 and thesecond syringe 13 are connected by a new unused three-way valve, so that thefirst syringe 10 and thethird syringe 14 are connected via the three-way valve. The contents of thefirst syringe 10 are transferred into thesecond syringe 13 through the three-way valve by rotating the piston to close the vent end. Finally, the vented end is communicated to thesecond syringe 13 by rotating the plunger, pulling thesecond syringe 13 plunger stem to draw the remaining contents of the three-way valve stem into thesecond syringe 13. Optionally, the vent end of the three-way valve may be provided with a sterilizing filter membrane.

Thesecond syringe 13 may be detachably connected to thespraying device 15 after being detached from the communicatingmember 11. Thethird injector 14 may be detachably connected to thespraying device 15, so that both thesecond injector 13 and thethird injector 14 can be connected to thespraying device 15, and the contents of thesecond injector 13 and thethird injector 14 are transferred into the sprayingdevice 15 by pushing the core rods of thesecond injector 13 and thethird injector 14, and are mixed in thespraying device 15 and then are sprayed out through the sprayingdevice 15.

Alternatively, thespray coating device 15 may include asupport frame 151, athrust plate 152, a spray tee, a nozzle, and a spray head. Thesecond syringe 13 and thethird syringe 14 may be held in parallel on the holdingframe 151. The spray tee may comprise two liquid inlets and one liquid outlet, wherein the two liquid inlets are respectively connected to the conical heads of thesecond injector 13 and thethird injector 14, and the liquid outlet is connected to the nozzle. Thus, the contents of the second andthird injectors 13, 14 can be transferred through the spray tee into the nozzle and mixed within the nozzle by pushing thepush plate 152. The nozzle is also internally provided with a spray head so as to atomize and spray the mixture in the nozzle.

Optionally, the conical head of thefirst syringe 10 may be detachably connected with a sheath when detached from the communicatingmember 11, so as to prevent the contents of thefirst syringe 10 from being contaminated by the external environment. Similarly, thesecond syringe 13 may be detachably connected with a sheath when thecommunication member 11 and thespraying device 15 are detached, and thethird syringe 14 may be detachably connected with a sheath when thespraying device 15 is detached.

Alternatively, thefirst syringe 10 may be connected to the communicatingmember 11 by a detachable sealing connection such as a luer fitting. Similarly, thesecond syringe 13 may be connected to thecommunication member 11 and thespraying device 15 by a detachable sealing connection, and thethird syringe 14 may be connected to thespraying device 15 by a detachable sealing connection. In addition, the conical head of thefirst syringe 10 may also have a needle assembly removably attached thereto.

Alternatively, thefirst syringe 10, thecommunication member 11, thecollection container 12, thesecond syringe 13 and thespraying device 15 may all be made of a transparent material such as plastic or glass, and the transfer of the substance from thefirst syringe 10 to thecollection container 12 through thecommunication member 11, the transfer of the substance from thefirst syringe 10 to thesecond syringe 13 through thecommunication member 11, and the transfer of the substance from thesecond syringe 13 and thethird syringe 14 to thespraying device 15 can all be clearly observed by the operator, so that the use of the extraction device of the present invention is convenient.

The process of PRP extraction and gel preparation using the extraction device of the present invention is schematically illustrated below with reference to fig. 3. It is noted that only thecommunication member 11 will be described below as a three-way valve as an example of the extraction method, and that thecommunication member 11 or other examples of the above-mentioned components may also be incorporated in the method below.

From the present viewpoint, it is generally considered that the recovery rate of PRP extracted by the secondary centrifugation technique is higher and PRP with a higher platelet concentration can be prepared than by the primary centrifugation technique. However, the inventors believe that the essence of extracting PRP is: sufficient centrifugation to ensure that cells are packed in a density gradient and tend to be constant, and disturbance reduction in separation of the PRP layer, therefore, the factor influencing the extraction of PRP is not to use a so-called primary centrifugation technique or a secondary centrifugation technique, but to influence the stable packing process of the centrifuged cells and whether disturbance is caused in collection of the corresponding components. Thus, the extraction efficiency of PRP by the secondary centrifugation technique is certainly better than that by the primary centrifugation technique. During the centrifugation process, the cell accumulation tends to be stable by adjusting the relative centrifugal force and the centrifugation time. In the PRP separation process, the reduced perturbation of the intermediate PRP layer prevents the platelets from spreading to the adjacent upper and lower layers, thereby collecting PRP with higher platelet recovery.

First, a predetermined amount of anticoagulant is drawn using thefirst syringe 10, and then a predetermined amount of blood is collected by mounting a needle assembly at the tapered end of thefirst syringe 10. The volume ratio of anticoagulant to the drawn blood may be 1:9 to effectively anticoagulate and maintain the stability of blood components. For example, 10 ml to 100 ml of blood is collected and 1 ml to 10 ml of anticoagulant is withdrawn accordingly. Subsequently, the needle assembly onfirst syringe 10 is removed and the sheath is fitted, andfirst syringe 10 is gently shaken to mix the anticoagulant and blood infirst syringe 10 to obtain anticoagulated blood. Thefirst syringe 10 is transferred to a centrifuge tube designed to match the shape and size of thefirst syringe 10 while keeping the conical head facing downward, and a balancing syringe containing water or blood and having the same specification as thefirst syringe 10 containing anticoagulated blood is further placed in another centrifuge tube of the centrifuge to achieve balancing and ensure the stability of the centrifugation process. Subsequently, the centrifuge is controlled to perform a centrifugation movement for 5 to 45 minutes at a relative centrifugal force ranging from 300 to 3000 g. The anticoagulated blood in thefirst syringe 10 is divided into a clear PPP layer, a PRP layer and a red blood cell layer from top to bottom. Among them, the separation is not clear enough when the relative centrifugal force or the centrifugal time is too short, and the blood cells are destroyed when the relative centrifugal force or the centrifugal time is too long, so that the conditions of hemolysis, platelet deformation or rupture and the like occur. Preferably, the centrifugation is carried out at a relative centrifugal force of 500g to 1500g for 15 minutes to 45 minutes, or at a relative centrifugal force of 1501g to 2500g for 10 minutes to 30 minutes, or at a relative centrifugal force of 2501g to 3500g for 5 minutes to 15 minutes.

The conical head of thefirst syringe 10 is held down on the split frame to ensure that the assembly process is stable to avoid undesired mixing of the layered components within thefirst syringe 10 and interference with the PRP located in the middle layer. The sheath of thefirst syringe 10 is detached and the three-way valve is sealingly connected to the conical head of thefirst syringe 10 via a luer fitting, and thecollection container 12 and thesecond syringe 13 are sealingly connected at the other two ends of the three-way valve via luer fittings, respectively. The three-way valve is adjusted to communicate thefirst syringe 10 with thecollection container 12, and the core rod of thefirst syringe 10 is pushed downward to transfer the lowermost red blood cells in thefirst syringe 10 into thecollection container 12 through thecommunication member 11. Preferably, thefirst syringe 10 transfers the layer of contained red blood cells into thecollection container 12 at a rate not exceeding 0.5 ml per second to smoothly discharge the red blood cells and reduce interference with the PRP layer, thereby stably ensuring recovery of platelets. Here, since there is a transition layer between the PRP layer and the red blood cell layer in thefirst syringe 10, it is preferable to transfer a part of the red blood cell layer in thefirst syringe 10 to thecollection container 12 while leaving a part of the red blood cell layer in thefirst syringe 10, particularly 3% to 10% of the volume of the blood collected in thefirst syringe 10, in order to secure extraction concentration and recovery rate of PRP as much as possible.

Keeping the conical head of thefirst syringe 10 downward, adjusting the three-way valve to communicate thefirst syringe 10 with thesecond syringe 13, pushing the core rod of thefirst syringe 10 downward, and transferring the PRP layer in thefirst syringe 10 into thesecond syringe 13, so that only the PRP layer is contained in thesecond syringe 13 to extract the PRP. Preferably, the time taken for thefirst syringe 10 to transfer the PRP layer into thesecond syringe 13 exceeds 10 seconds, so as to avoid adhesion of the tunica albuginea layer after blood centrifugation to the red blood cells remaining on the vessel wall due to an excessively fast separation speed, thereby reducing interference on the PRP layer, stably performing extraction of PRP, and further ensuring stable platelets and recovery rate in PRP. Subsequently, thesecond syringe 13 is detached from the three-way valve and the sheath is fitted at the conical head.

Illustratively, the inventors have tested that in the case of 10 ml of blood collected by thefirst syringe 10 under the same centrifugation conditions, thefirst syringe 10 retains 0.3 ml to 1 ml of red blood cells transferred with the PRP layer into thesecond syringe 13, and the PRP transferred from thefirst syringe 10 into thesecond syringe 13 is 1 ml to 2 ml. In the case of 20 ml of blood collected through thefirst syringe 10, 0.6 ml to 2 ml of red blood cells retained by thefirst syringe 10 are transferred to thesecond syringe 13 along with the PRP layer, and the PRP transferred from thefirst syringe 10 to thesecond syringe 13 is 2 ml to 4 ml. In the case of collecting 30 ml of blood through thefirst syringe 10, thefirst syringe 10 retains 1 ml to 3 ml of red blood cells and the PRP layer is transferred into thesecond syringe 13, and the PRP transferred from thefirst syringe 10 into thesecond syringe 13 is 3 ml to 6 ml. In the case of collecting 50 ml of blood through thefirst syringe 10, 1.5 ml to 5 ml of red blood cells retained by thefirst syringe 10 are transferred to thesecond syringe 13 along with the PRP layer, and the PRP transferred from thefirst syringe 10 to thesecond syringe 13 is 5 ml to 10 ml. In the case of collecting 100 ml of blood through thefirst syringe 10, thefirst syringe 10 retains 3 ml to 10 ml of red blood cells and the PRP layer is transferred into thesecond syringe 13, and the PRP transferred from thefirst syringe 10 into thesecond syringe 13 is 10 ml to 20 ml.

In one specific example, thefirst syringe 10 collects 30 milliliters of blood and is centrifuged at a relative centrifugal force of 2200g for 20 minutes. 1 ml to 3 ml of red blood cells are retained in thefirst syringe 10 and transferred with the PRP layer into thesecond syringe 13. the PRP transferred from thefirst syringe 10 into thesecond syringe 13 may be 3 ml to 6 ml. In the case where the PRP extracted in thesecond syringe 13 was 5 ml, the average values of the platelet count in 30 ml of blood in thefirst syringe 10, the platelet count in 5 ml of PRP transferred to thesecond syringe 13, the platelet count in 19 ml of PPP left in thefirst syringe 10, and the platelet count in 5.8 ml of red blood cells transferred to thecollection container 12 were (602 ± 54) × 10, respectively, as observed by an optical microscope⁹size/L, (2903 +/-91) × 10⁹Per liter, (130 +/-1) multiplied by 10⁹Per liter, (69 +/-1) multiplied by 10⁹And (2) per liter. The ratio of the platelet count of PRP to that of blood was calculated to obtain an enrichment factor, i.e., (2903X 10)⁹)/(602×10⁹) 4.80. In addition, the actual number of platelets in PRP, i.e.,5X 10, was calculated from the platelet count and PRP volume of PRP^-3×2903×10⁹And (4) respectively. The actual number of platelets in the blood, i.e. 30 x 10, was calculated from the platelet count and blood volume of the blood^-3×602×10⁹And (4) respectively. Finally, the recovery of platelets, i.e., (5X 2903X 10) is obtained from the actual number of platelets in the PRP and the actual number of platelets in the blood⁹)/(30×602×10⁹) 80.4%. In conclusion, the method according to the present invention can adjust the final platelet enrichment factor by controlling the volume of thefirst syringe 10 transferred into thesecond syringe 13, and the extracted PRP has high platelet recovery rate and good extraction effect.

Furthermore, the time required to prepare PRP using a prior art apparatus for extracting PRP using a single centrifugation technique generally takes 15 minutes, and accordingly the platelet enrichment factor is approximately determined at 5 and the platelet recovery rate is approximately 60% or 62%. The time for preparing PRP using the apparatus for extracting PRP by the double centrifugation technique usually takes 20 minutes, and accordingly the platelet enrichment factor is roughly determined to be 6.40 ± 1.06 or 7.6 ± 1.2 and the platelet recovery rate is roughly (60.85 ± 8.97)% or (80.3 ± 12.8)%. In contrast, the device of the present invention for PRP preparation uses a single centrifugation technique, typically 15 minutes for preparation time, adjustable enrichment factor in the range of 3 to 10, and approximately (82 ± 14.5)%.

The thrombin is prepared by drawing a physiological saline solution using thethird syringe 14, mounting a sheath on the tip of thethird syringe 14, gently shaking thethird syringe 14, and mixing the physiological saline solution and thrombin in thethird syringe 14 to obtain the coagulant. The conical heads of thesecond syringe 13 containing the PRP and thethird syringe 14 containing the coagulant are placed side by side with the conical heads facing down on thesupport frame 151, and apush plate 152 is attached to the head of the core rod of thesecond syringe 13 and thethird syringe 14. The sheaths at the conical heads of thesecond injector 13 and thethird injector 14 are detached, two liquid inlets of the spraying tee are respectively connected to the conical heads of thesecond injector 13 and thethird injector 14 through luer connectors, and a nozzle with a built-in spraying head is connected to a liquid outlet of the spraying tee. The operator may then push thepush plate 152 downward to push thesecond syringe 13 and thethird syringe 14 core pins, and the PRP in thesecond syringe 13 and the coagulant in thethird syringe 14 are pushed into the nozzle where they mix to produce a PRP gel, which is finally atomized by the spray head.

It should be understood that any combination of the operation steps of the extraction device in this embodiment to extract PRP should fall within the protection scope of the present invention.

It should be understood that although the description is in terms of various embodiments, not every embodiment includes only a single embodiment, and such description is for clarity purposes only, and those skilled in the art will recognize that the embodiments described herein may be combined as suitable to form other embodiments, as will be appreciated by those skilled in the art.

The above description is only an exemplary embodiment of the present invention, and is not intended to limit the scope of the present invention. Any equivalent alterations, modifications and combinations can be made by those skilled in the art without departing from the spirit and principles of the invention.

Claims (15)

Translated fromChinese

1.一种从血液中提取富血小板血浆的方法，其特征在于，所述方法包括：1. a method for extracting platelet-rich plasma from blood, wherein the method comprises:使内含经抗凝处理的血液的第一注射器(10)的锥头朝下，并将所述第一注射器(10)以300g至3000g的相对离心力离心5分钟至45分钟，所述第一注射器(10)内的内容物自上而下分层为贫血小板血浆层、富血小板血浆层和红细胞层；The cone head of the first syringe (10) containing the anticoagulated blood is turned down, and the first syringe (10) is centrifuged at a relative centrifugal force of 300g to 3000g for 5 minutes to 45 minutes, and the first syringe (10) is centrifuged for 5 minutes to 45 minutes. The contents in the syringe (10) are layered into platelet-poor plasma layer, platelet-rich plasma layer and red blood cell layer from top to bottom;保持所述第一注射器(10)的锥头朝下，并将所述第一注射器(10)经由联通件(11)流体连通地连接至收集容器(12)，使所述第一注射器(10)内的红细胞层经由所述联通件(11)转移至所述收集容器(12)内；Keeping the cone head of the first syringe (10) facing down, and connecting the first syringe (10) in fluid communication with the collection container (12) via the communication piece (11), the first syringe (10) The red blood cell layer in ) is transferred into the collection container (12) through the communication piece (11);保持所述第一注射器(10)的锥头朝下，并将所述第一注射器(10)经由所述联通件(11)流体连通地连接至第二注射器(13)，使所述第一注射器(10)内的富血小板血浆层经由所述联通件(11)转移至所述第二注射器(13)内，以使所述第二注射器(13)内仅含富血小板血浆层；Keeping the cone head of the first syringe (10) facing down, and connecting the first syringe (10) in fluid communication with the second syringe (13) via the communication piece (11), the first syringe (10) is connected in fluid communication with the second syringe (13) The platelet-rich plasma layer in the syringe (10) is transferred into the second syringe (13) through the communication piece (11), so that the second syringe (13) only contains the platelet-rich plasma layer;将内含富血小板血浆的所述第二注射器(13)和内含凝血剂的第三注射器(14)流体连通地连接至喷涂装置(15)；connecting said second syringe (13) containing platelet rich plasma and a third syringe (14) containing coagulant to a spray device (15) in fluid communication;将所述第二注射器(13)内的富血小板血浆和所述第三注射器(14)内的凝血剂转移至所述喷涂装置(15)，并使所述喷涂装置(15)内的富血小板血浆和凝血剂混合产生富血小板凝胶并从所述喷涂装置(15)内喷出。Transfer the platelet rich plasma in the second syringe (13) and the coagulant in the third syringe (14) to the spraying device (15), and make the platelet rich plasma in the spraying device (15) The plasma and coagulant are mixed to produce a platelet rich gel and sprayed from the spray device (15).2.根据权利要求1所述的方法，其特征在于，经抗凝处理的血液通过如下步骤得到：2. The method according to claim 1, wherein the anticoagulated blood is obtained by the following steps:使用所述第一注射器(10)抽取抗凝剂；using the first syringe (10) to withdraw anticoagulant;使用所述第一注射器(10)采集血液，所述第一注射器(10)抽取的抗凝剂与采集的血液之间的比例为1:9；Using the first syringe (10) to collect blood, the ratio between the anticoagulant drawn from the first syringe (10) and the collected blood is 1:9;将所述第一注射器(10)内的抗凝剂和血液混合，得到经抗凝处理的血液。The anticoagulant and blood in the first syringe (10) are mixed to obtain anticoagulated blood.3.根据权利要求2所述的方法，其特征在于，所述第一注射器(10)采集的血液的体积范围为10毫升至100毫升。3. The method according to claim 2, wherein the volume of the blood collected by the first syringe (10) ranges from 10 ml to 100 ml.4.根据权利要求1所述的方法，其特征在于，所述第一注射器(10)以500g至1500g的相对离心力离心15分钟至45分钟。4. The method according to claim 1, wherein the first syringe (10) is centrifuged at a relative centrifugal force of 500g to 1500g for 15 minutes to 45 minutes.5.根据权利要求1所述的方法，其特征在于，所述第一注射器(10)以1501g至2500g的相对离心力离心10分钟至30分钟。5. The method according to claim 1, wherein the first syringe (10) is centrifuged at a relative centrifugal force of 1501 g to 2500 g for 10 to 30 minutes.6.根据权利要求1所述的方法，其特征在于，所述第一注射器(10)以2501g至3500g的相对离心力离心5分钟至15分钟。6. The method according to claim 1, wherein the first syringe (10) is centrifuged at a relative centrifugal force of 2501 g to 3500 g for 5 minutes to 15 minutes.7.根据权利要求1所述的方法，其特征在于，所述第一注射器(10)以不超过每秒0.5毫升的速度将内含的红细胞层转移至所述收集容器(12)内。7. The method according to claim 1, wherein the first syringe (10) transfers the contained red blood cell layer into the collection container (12) at a rate not exceeding 0.5 milliliters per second.8.根据权利要求1所述的方法，其特征在于，所述第一注射器(10)仅将红细胞层的一部分转移至所述收集容器(12)，而在第一注射器(10)内留有红细胞层的剩余部分。8. The method according to claim 1, characterized in that the first syringe (10) transfers only a part of the red blood cell layer to the collection container (12), while leaving in the first syringe (10) The remainder of the red blood cell layer.9.根据权利要求8所述的方法，其特征在于，所述第一注射器(10)内留有的红细胞的体积范围为所采集的血液的体积的3％至10％。9. The method according to claim 8, wherein the volume of red blood cells remaining in the first syringe (10) ranges from 3% to 10% of the volume of the collected blood.10.根据权利要求1所述的方法，其特征在于，所述第一注射器(10)将富血小板血浆层转移至所述第二注射器(13)内所需时间超过10秒。10. The method of claim 1, wherein the time required for the first syringe (10) to transfer the platelet rich plasma layer into the second syringe (13) exceeds 10 seconds.11.根据权利要求1所述的方法，其特征在于，凝血剂通过如下步骤得到：11. The method according to claim 1, wherein the coagulant is obtained by the following steps:使用所述第三注射器(14)抽取生理盐水；using the third syringe (14) to withdraw physiological saline;使用所述第三注射器(14)配制凝血酶，并将所述第三注射器(14)内的生理盐水和凝血酶混合，得到凝血剂。Thrombin is prepared by using the third syringe (14), and the physiological saline and thrombin in the third syringe (14) are mixed to obtain a coagulant.12.一种从血液中提取富血小板血浆的装置，其用于执行如权利要求1至11中任一项所述的方法，其特征在于，所述装置包括：12. A device for extracting platelet-rich plasma from blood for performing the method of any one of claims 1 to 11, wherein the device comprises:第一注射器(10)，其内含经抗凝处理的血液，并将其以锥头朝下的姿态以300g至3000g的相对离心力离心5分钟至45分钟，所述第一注射器(10)内的内容物自上而下分层为贫血小板血浆层、富血小板血浆层和红细胞层；A first syringe (10), which contains anticoagulated blood, is centrifuged for 5 minutes to 45 minutes at a relative centrifugal force of 300g to 3000g with the cone head facing down, and the first syringe (10) The contents of the cell are stratified from top to bottom into the platelet-poor plasma layer, the platelet-rich plasma layer, and the red blood cell layer;联通件(11)，所述第一注射器(10)以锥头朝下姿态可拆卸连接至所述联通件(11)；a communication piece (11), the first syringe (10) is detachably connected to the communication piece (11) with the cone head facing downwards;收集容器(12)，其可拆卸连接至所述联通件(11)，从而使所述第一注射器(10)和所述收集容器(12)经由所述联通件(11)联通，且所述第一注射器(10)内的红细胞层经由所述联通件(11)转移至所述收集容器(12)内；a collection container (12), which is detachably connected to the communication piece (11), so that the first syringe (10) and the collection container (12) are communicated via the communication piece (11), and the The red blood cell layer in the first syringe (10) is transferred into the collection container (12) via the communication piece (11);第二注射器(13)，其可拆卸连接至所述联通件(11)，以使所述第一注射器(10)内的富血小板血浆层经由所述联通件(11)转移至所述第二注射器(13)内，以使所述第二注射器(13)内仅含富血小板血浆层而提取出富血小板血浆。A second syringe (13), which is detachably connected to the communication piece (11), so that the platelet rich plasma layer in the first syringe (10) is transferred to the second via the communication piece (11) inside the syringe (13), so that the second syringe (13) only contains the platelet-rich plasma layer to extract the platelet-rich plasma.喷涂装置(15)，内含富血小板血浆的所述第二注射器(13)在与所述联通件(11)拆离后可拆卸连接至所述喷涂装置(15)；a spraying device (15), wherein the second syringe (13) containing platelet-rich plasma is detachably connected to the spraying device (15) after being detached from the communication member (11);第三注射器(14)，其内含有凝血剂且与所述喷涂装置(15)可拆卸连接，以使所述第二注射器(13)、所述第三注射器(14)和所述喷涂装置(15)流体连通，所述第二注射器(13)内的富血小板血浆和所述第三注射器(14)内的凝血剂能够转移至所述喷涂装置(15)，并在所述喷涂装置(15)内混合产生富血小板凝胶后喷出。A third syringe (14), which contains a coagulant and is detachably connected to the spraying device (15), so that the second syringe (13), the third syringe (14) and the spraying device ( 15) In fluid communication, the platelet rich plasma in the second syringe (13) and the coagulant in the third syringe (14) can be transferred to the spraying device (15) and in the spraying device (15) ) to produce a platelet-rich gel and then ejected.13.根据权利要求12所述的装置，其特征在于，所述第一注射器(10)、所述收集容器(12)、所述第二注射器(13)和所述第三注射器(14)的锥头均可拆卸连接有护套。13. The device according to claim 12, characterized in that the first syringe (10), the collection container (12), the second syringe (13) and the third syringe (14) are The cone head can be detachably connected with a sheath.14.根据权利要求12所述的装置，其特征在于，所述联通件(11)为二通阀或三通阀。14. The device according to claim 12, characterized in that, the communication member (11) is a two-way valve or a three-way valve.15.根据权利要求12所述的装置，其特征在于，所述喷涂装置(15)包括：15. The device according to claim 12, wherein the spraying device (15) comprises:支撑架(151)，其将所述第二注射器(13)和所述第三注射器(14)彼此并置地夹持在其中；a support frame (151), which holds the second syringe (13) and the third syringe (14) juxtaposed with each other therein;推进板(152)，其安装至所述第二注射器(13)和所述第三注射器(14)芯杆的头部；a pusher plate (152) mounted to the heads of the plungers of the second syringe (13) and the third syringe (14);喷雾三通，其包括两个进液口和一个出液口，所述喷雾三通的两个进液口分别连接至所述第二注射器(13)和所述第三注射器(14)的锥头；A spray tee, comprising two liquid inlets and one liquid outlet, and the two liquid inlets of the spray tee are respectively connected to the cones of the second syringe (13) and the third syringe (14) head;喷嘴，其连接至所述喷涂三通的出液口，以使所述第二注射器(13)和所述第三注射器(14)以及所述喷嘴相互连通，第二注射器(13)内的富血小板和所述第三注射器(14)内的凝血剂转移进入所述喷嘴内而在所述喷嘴内混合产生凝胶；a nozzle, which is connected to the liquid outlet of the spraying tee, so that the second syringe (13), the third syringe (14) and the nozzle communicate with each other, and the rich in the second syringe (13) The platelets and the coagulant in the third syringe (14) are transferred into the nozzle where they mix to produce a gel;喷雾头，其安装至所述喷嘴内，以将凝胶雾化后喷出。A spray head is installed into the nozzle to atomize and spray the gel.

Images